國家衛生研究院 NHRI:Item 3990099045/7201
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 856794      在线人数 : 906
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/7201


    题名: Auy922, a novel Hsp90 inhibitor effective against ABC-dlbcl and malt lymphoma cells harboring genetic alteration-associated NF-kappa B activation
    其它题名: Auy922, a novel Hsp90 inhibitor effective against ABC-dlbcl and malt lymphoma cells harboring genetic alteration-associated NF-κB activation
    作者: Chen, LT;Tsai, HJ;Kuo, SH;Cheng, AL
    贡献者: National Institute of Cancer Research
    摘要: Purpose: Recurrent genetic alterations that are frequently observed in activated B cell subtype of diffuse large B cell lymphoma (ABC-DLBCL) and mucosa-associated lymphoid tissue type lymphoma (MALT lymphoma), such as mutation of MYD88, CD79a, CD79b and CARD11 in the former and t(11;18), t(1;14) and t(14;18) in the latter, are usually associated with NF-kB activation and confer resistance to therapy. In this study, we investigate the therapeutic efficacy and molecular mechanisms of AUY922, a novel HSP90 inhibitor, on representative cell lines - OCI-Ly3 (ABC-DLBCL with CARD11 and MYD88 mutations) and MA-1 (MALT lymphoma cells with t(14;18) translocation). Methods: OCI-Ly3 and MA-1 cells were treated with various concentration of AUY922 or 17-AAG for 48 to 72 hrs, and then subjected for WST1 assay for determining cell viability and IC50. After demonstrating the growth inhibition efficacy, the cells were treated with fixed dose of AUY922 or 17-AAG for 0 to 48 or 72 hrs and subjected for annexin V/propidium iodide apoptotic assay, cell cycle analysis, and Western blot analysis to evaluate the expression levels of total and some phosphorylated forms of PI3K/Akt/GSK3a/b/mTOR/4-EBP1/P70S6, cyclin D1, Raf-B/MEK1/2/MAPK, NK-kB p100/p52, Mcl-1, Bcl-2, Bax, Bik, BID, Bak, Bad, PARP, caspase-3, caspase-9, a-actinin, GAPDH, and HSP70. Results: Our results showed that AUY-922, in contrast to 17-AAG, effectively inhibited the proliferation and induced apoptosis of OCI-Ly3 and MA-1 cells with IC50 of 20-30 nM. AUY922 also significantly downregulated the expression of molecules of multiple signaling pathways, including PI3K/AKT/GSK3a/b/mTOR, Raf/MEK/MAPK, JAK/STAT3, and NF-kB as well as mitochondrial apoptotic pathway-related anti-apoptotic Bcl-2 family proteins, in both cell lines. Conclusions: The results highlight that AUY-922, but not 17-AAG, can effectively against the two B-cell lymphoma cell lines with genetic alteration-associated NK-kB activation, the OCI-Ly3 and MA-1 cells. The findings indicate the potential use of AUY922 in resistant or refractory B-cell lymphoma patients and deserves further clinical investigation.
    日期: 2013-03
    關聯: Annals of Oncology. 2013 Mar;24(Suppl. 1):24-25.
    Link to: http://dx.doi.org/10.1093/annonc/mdt045.7
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0923-7534&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000316125600064
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85081682056
    显示于类别:[陳立宗] 會議論文/會議摘要
    [蔡慧珍] 會議論文/會議摘要

    文件中的档案:

    档案 描述 大小格式浏览次数
    ISI000316125600064.pdf31KbAdobe PDF583检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈